Recital 6, Regulation (EU) 2024/2699

In forcesince 18 Oct 2024

The information on upcoming marketing authorisation applications, as well as certain other available information related to the planning and forecast of the joint clinical assessments and joint scientific consultations, is based, inter alia, on the information shared by health technology developers with the European Medicines Agency on a voluntary basis and it may contain commercially confidential data. In addition to the requirements of Article 5(6) and Article 30(3), point (m), of Regulation (EU) 2021/2282, appropriate and specific measures to protect adequately this and other confidential information received by the HTA secretariat from the European Medicines Agency within the context of joint clinical assessment and joint scientific consultation should be set out in this Implementing Regulation. This is necessary in order to ensure that such information is protected not only at the level of the Coordination Group or its subgroups, but also at the level of their members, including where the access to that information is given to other individuals who might be involved in joint clinical assessment and joint scientific consultation by the members of the Coordination Group and its subgroups. Moreover, in order to safeguard the appropriate protection of confidential information shared by the European Medicines Agency within the context of joint clinical assessment and joint scientific consultation, it is appropriate to specify the purposes for which the information received from the European Medicines Agency may be used and set out the rules on how the level of protection is attributed. Without prejudice to any legal or criminal proceedings by the competent national authorities of the Member States in accordance with their laws and regulations and to contractual remedies, in case of breaches or failure to respect the obligations of professional secrecy, appropriate measures should be taken.